We are exiting $BCRX and $AVAV; please see separate posts for the reasons. We are short on $ACOR with average price of $30.28. Our thesis has not changed in that Ampyra is not a very good drug, although Wall Street has termed it a blockbuster drug. . In the short
In the past three weeks, Lampert and his key investors sold more than $538M in AutoZone . We are still short on $AZO and its competitors. The latest argument advanced by supporters of these stocks is that reduction of dealers by GM and Chrysler benefits these stocks. Such Gurus claim
Our long term readers know that we have been short on $AZO and its competitors. Last night Lampert indicated in a filing that he sold 454K shares and distributed another 2.6M shares. This sale seems to support our thesis on staying short on $AZO, $ORLY, and $AAP. www.thearorareport.com THE ARORA
Consider adding to short positions on AZO around $158.15, AAP around $44.8 and ORLY around $38.11. Add more on spikes up www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since
Auto parts stocks such as ORLY (O’Reilly Automotive), AAP (Advanced Auto Parts), and AZO (Auto Zone) have continued to levitate on the theory that consumers will continue to keep their old cars. This view does not square well with improving consumer sentiment numbers. Further, there is a very high probability